Adnectin EGFR/IGFR inhibitor (Adnexus/BMS)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug NameAdnectin EGFR/IGFR inhibitor (Adnexus/BMS)
Drug Alias NameEGFR/IGFR tandem adnectin (Bristol-Myers Squibb/Adenxus)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionEpidermal growth factor receptor erbB1 modulatorsSomatomedin receptors antagonists
TargetsSomatomedin receptorsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol-Myers Squibb Company
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A